Bio-Integrative Versus Metallic Screws for Calcaneus Osteotomies

Sponsor
University of Iowa (Other)
Overall Status
Recruiting
CT.gov ID
NCT05018130
Collaborator
(none)
44
1
2
13
3.4

Study Details

Study Description

Brief Summary

The use of bio-integrative implants in orthopedic surgery is growing exponentially. As many biomechanical and histological studies were able to sustain its structural and biological properties, few clinical studies are available to support its advantages, such as good osteosynthesis, lower rates of removal, and diminished implant-related artifact in imaging studies. This information is vital to providers when choosing the proper material and planning postoperative treatment. This trial intends to test the capacity of the bioabsorbable screws in reaching the same clinical and radiographical outcomes of the current metallic screws.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Calcaneus Osteotomy (Metallic)
  • Procedure: Calcaneus Osteotomy (Bio-integrative)
N/A

Detailed Description

A minimum of 44 patients undergoing Medial or Lateral Displacement Calcaneal Osteotomy (MDCO) will be randomized in two parallel groups for surgery, considering applied the implant. One group will be operated using two 4.0mm cannulated bio-integrative (absorbable) screws, and the other group using two 4.0mm cannulated metallic screws. Patients will be blinded evaluated for a mean follow-up of twelve weeks in terms of bone healing, complications, and implant-related artifact using weight-bearing computed tomography (WBCT).

Study Design

Study Type:
Interventional
Anticipated Enrollment :
44 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Randomized, investigator-blinded, in parallel groups, two-arms, single-center, non-inferiority, clinical trial.Randomized, investigator-blinded, in parallel groups, two-arms, single-center, non-inferiority, clinical trial.
Masking:
Double (Investigator, Outcomes Assessor)
Masking Description:
The evaluator doctor will not have access to the protocol test applied to each patient and the surgeries will be conducted by different physicians.
Primary Purpose:
Treatment
Official Title:
Bio-Integrative Versus Metallic Screws for Calcaneus Osteotomies: A Non- Inferiority Randomized Clinical Trial
Actual Study Start Date :
Nov 1, 2021
Anticipated Primary Completion Date :
Jul 30, 2022
Anticipated Study Completion Date :
Dec 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Bio-integrative

Traditional oblique calcaneus osteotomy through a lateral approach. After a 10mm displacement, the osteotomy will be fixed with two 4.0mm bio-integrative cannulated screws.

Procedure: Calcaneus Osteotomy (Bio-integrative)
Calcaneus Displacement Osteotomy using two bio-integrative screws

Active Comparator: Metallic

Traditional oblique calcaneus osteotomy through a lateral approach. After a 10mm displacement, the osteotomy will be fixed with two 4.0mm metallic cannulated screws.

Procedure: Calcaneus Osteotomy (Metallic)
Calcaneus Displacement Osteotomy using two metallic screws

Outcome Measures

Primary Outcome Measures

  1. Bone healing [6 weeks]

    - Amount of bone bridging crossing the osteotomy site: Determined by the percentage of bone trabeculae crossing the osteotomy site on every tomography cut (amount of the cut in millimeters that shows bone spanning the two fragments divided by the total amount of osteotomy's surface on the cut). - Weight-bearing computed tomography (WBCT) acquisitions will be used to determine this percentage.

Secondary Outcome Measures

  1. Complications [6 weeks]

    - Percentage of minor and major complications: Dehiscence: inability to heal the soft tissue coverage until the end of the 4th post-operative week. Peripherical nerve damage: hypoesthesia or paresthesia not solved until the 6th week after the surgery. Infection: clinical signs of site infection or pus drainage at the wound that required antibiotics.

  2. Implant-related artifact [6 weeks]

    - Quantity of Hounsfield units around the implants Measured on WBCT acquisitions.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 85 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Individuals must be older than 18 and younger than 75 years of age, both genders;

  • Participants must be experiencing symptoms related to their baseline condition for at least six months before the surgery;

  • Clinical diagnosis of hindfoot malignment, defined as the presence of a clinical hindfoot angle above 10 degrees of valgus or any degree of varus;

  • Surgical planning, including a calcaneus displacement osteotomy through a traditional oblique cut.

Exclusion Criteria:
  • Previous surgery involving the affected calcaneus;

  • History or documented evidence of autoimmune or peripheral vascular diseases;

  • History or documented evidence of peripheral neuropathy (nervous compression syndrome, tarsal tunnel syndrome) or systemic inflammatory disease a (rheumatoid arthritis, spondylitis, Reiter Syndrome, etc.);

  • Any condition that represents a contraindication of the proposed therapies;

  • Impossibility or incapacity to sign the informed Consent Form;

  • Presence of infectious process (superficial on the skin and cellular tissue, or deep in the bone) in the region to be treated.

  • Osteotomies requiring resection of wedges (Dweyer, triple Dweyer, etc.);

  • Osteotomies planned to occur in a non-traditional cut (Malerba, Scarf, etc.).

Contacts and Locations

Locations

Site City State Country Postal Code
1 Departament of Orthopaedics and Rehabilitation, University of Iowa, Carver College of Medicine Iowa City Iowa United States 52241

Sponsors and Collaborators

  • University of Iowa

Investigators

  • Principal Investigator: Cesar de Cesar Netto, MD, PhD, Assistant Professor
  • Study Director: Nacime Salomao Barbachan Mansur, Visiting Associate

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Cesar De Cesar Netto, Assistant Professor, University of Iowa
ClinicalTrials.gov Identifier:
NCT05018130
Other Study ID Numbers:
  • 202106228
First Posted:
Aug 24, 2021
Last Update Posted:
May 20, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Cesar De Cesar Netto, Assistant Professor, University of Iowa
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 20, 2022